and rs12632942 (P1092), respectively. 10 The substantial arrhythmogenic potential of genetic variants in SCN10A is underscored by the fact that another SNP (rs10428132) in this gene was the top hit in a GWAS on Brugada syndrome; a condition strongly associated with AF. 14, 15 Moreover, recently, a phenome-wide study associated SCN10A, through rs6795970, directly with AF. 16 This, however, contradicts with the findings by Holm et al who did not report an association of rs6795970 with AF. 11 SCN10A encodes the voltage-gated sodium channel, Na v 1.8. This channel is the predominant tetrodotoxin-resistant sodium channel in primary sensory neurons, with particularly high levels of expression in nociceptive neurons, where it plays a key role in peripheral pain processing. 17, 18 Expression has also been shown in vagal, but not in sympathetic fibers. 19, 20 Recently, several studies have indicated that SCN10A mRNA is present in both human and mouse heart and that this channel is involved in the cardiac I Na current. 9, [21] [22] [23] Yang et al demonstrated higher expression of Na v 1.8 transcripts in mouse atria compared with ventricle. 21 Facer et al detected Na v 1.8 protein in both atrial myocytes and nerve fibers in the myocardium. 24 Using genetic lineage tracing, others have shown that Na v 1.8 is expressed in aortic bodies and the nerves around blood vessels of the heart. 20 Interestingly, Verkerk et al found that Na v 1.8 is highly expressed in intracardiac neurons. 22 In summary, these studies suggest that Na v 1.8 is expressed in both cardiac myocytes and intracardiac neurons.
The recent notion that Na v 1.8 might be important for cardiac electrophysiological properties raises the possibility that altered function of this gene may be coupled with cardiac arrhythmias. 25 Thus, in the present study, we investigated whether the common SCN10A variant rs6795970 is associated with AF and thereby would be the variant carrying the effect of the GWAS hit. In addition, we screened 225 lone AF patients for SCN10A variants and characterized the 2 rarest variants together with the 2 common variants functionally using patch-clamp electrophysiology.
Methods

Study Subjects
Patient records with the ICD-10 diagnose code I48.9 (atrial fibrillation and flutter) were collected and read. Only 225 patients with lone AF and onset of disease before age of 40 years were recruited. Lone AF was defined as AF in absence of clinical or echocardiographic findings of cardiovascular disease, hypertension requiring medical therapy, metabolic, or pulmonary diseases. For the genotyping of the rs6795970 SNP, we recruited a cohort of 358 Scandinavian lone AF patients with onset of AF before the age of 50 (83% male sex, median age of AF onset 34.5 years [interquartile range 28-39 years]), and a cohort of 157 unselected AF patients (68% male sex, median age of 66 years [interquartile range 32-86 years]; in the Data Supplement). Blood samples, ECG, and clinical data were collected from all participating subjects. The study conforms to the principles outlined in the Declaration of Helsinki and was approved by the local scientific ethics committees, and all patients provided written informed consent.
Control Population
A total of 730 healthy subjects (52% males, median 66 years [interquartile range 52-76 years]) from 2 control cohorts (control groups I and II) were included in this study (in the Data Supplement). Control group I (complete sequencing of SCN10A) consisted of 216 unrelated healthy Danish blood donors with a normal ECG and without any cardiac symptoms. Control group II comprised 514 ethnically matched, middle-aged men and women without a history of AF or other manifestations of cardiovascular disease, however, with a high prevalence of risk factors for AF. Control groups I and II were previously described in detail. 26, 27 These control groups were used in the genotyping of rs6795970 using a Taqman assay. To increase the statistical power of our association study, we also used a third control cohort (control group III), comprising 6161 individuals randomly selected from a Danish cohort study (Inter99, LuCamp). 28 This control cohort could only provide data on rs6795970 as a result of the exome-chip which was used in the Inter99 study. This control group is assumed to represent the general population.
SCN10A Screening
The method is available in the Data Supplement.
SNP Genotyping
We genotyped rs6795970, encoding A1073, in 515 AF patients of which 358 were lone AF patients. For comparison, in addition to control groups I and II (n Total =730), we also used the data from a European American population (n=4300) from the exome sequencing project (ESP). Genotyping of control groups I and II was performed as previously described. 26 Furthermore, we also used the exome-chip data on the rs6795970 SNP from control group III.
Molecular Biology and In vitro Electrophysiology
Introduction of variants, cell culturing, and patch-clamping of transiently transfected Neuro2A cells were performed as previously described. 29 A detailed description is available in the Data Supplement.
Bioinformatics and Statistical Analysis
All variants were reviewed in publicly available SNP databases (db-SNP and ESP6500). We used 4 in silico tools to predict whether the variants were disease causing. The minor allele frequency (MAF) in the 2 case cohorts were compared one by one with the 3 control cohorts using the chi-square test. Similarly, we performed a pooled analysis where MAF in the 2 case groups were compared with a pooled MAF from our largest control population and ESP. Data are presented as mean±standard error of mean (SEM) unless otherwise noted. Kolmogorov-Smirnov test was applied to confirm Gaussian distribution. Two-tailed Student's t test, 1-way or 2-way analysis of variance combined with a Bonferroni post hoc test, or chi-square tests were used as appropriate to test for significant differences. A value of P<0.05 was considered statistically significant. Further description is available at the Data Supplement.
Results
Genetic Screening
We included 225 unrelated Danish patients with onset of disease before the age of 40 years for full genetic screening (clinical data listed in the Data Supplement). The individual clinical characteristics of the patients with the rare SCN10A variations are listed in Table 1 . In Figure 1 , the positions of rare and common missense variants found in SCN10A in lone AF are illustrated in the Na v 1.8 protein topology. We identified 9 rare missense variants (R14L, V94G, Y158D, R814H, E825D, I999L, R1268Q, C1523Y, and R1588Q) and one splice site donor variant (rs75991777; in exon 4 at second position T>C; Table 2 ). These variants were neither present in our in-house control group (n=432 alleles) nor have any been previously reported in conjunction with AF. However, except for I999L and rs75991777, all variants were identified in the Exome Sequencing Project database (n=6503) with minor allele frequency (MAF) <0.5% in the European American population. rs75991777 has been reported in the dbSNP database from the 1000 Genomes Project with a MAF of 0.1%. The amino acid residues altered in the rare variants were found to be highly conserved across eukaryotic species, except for R814H and E825D, which differed in rat and mouse (data not shown). In our cosegregation analysis, we were able to screen the family members of the patients with I999L, C1523Y, and rs75991777 variants. None of the family members diagnosed with AF Positions and clinical characteristics of the patients with rare variants with minor allele frequencies (MAF) <0.5% in the European American (EA) in the Exome Sequencing Project (n=6503, ESP6500) server. AF indicates atrial fibrillation; AVNRT, AV-nodal re-entry tachycardia; ICD, implantable cardioverter-defibrillator; IRBBB, incomplete right bundle-branch block; RFA, radiofrequency ablation; SR, sinus rhythm; SVPC, supraventricular premature complexes; SCD, sudden cardiac death; and VT, ventricular tachycardia. carried the variant identified in the probands. Family members of remaining geno-positive patients were not available. PolyPhen2 prediction software predicted 78% (7 out of 9) of the rare variants to have a functional effect on protein function ( Table 2 ). 30 By using the Giudicessi et al agreement of ≥3 in silico tools on these rare variants, it was predicted that 60% of the variants were damaging ( Table 2 ). 31
Genotyping of rs6795970 Encoding A1073
The result of the SNP genotyping is listed in Table 3 ).
These results indicate that rs6795970 increases the risk of developing AF (Table 3) .
Clinical Features
Nine out of 11 of the AF patients harboring an SCN10A variant had paroxysmal AF, and several of these patients also had other arrhythmias ( Table 1 ). The R14L variant was identified in a patient with paroxysmal AF with onset of AF at age 31 and AV-nodal re-entry tachycardia (AVNRT). The V94G variant was found in 2 patients with paroxysmal and persistent AF with an onset of disease at age 28 and 27, respectively. The missense variants Y158D and R814H were identified in a patient with persistent AF with onset at age 31, who had several radiofrequency ablation procedures for AF. The paroxysmal AF patient with onset of disease at age 35 had a splice-site donor variant at exon 4. This patient had normal coronary angiography with atrial flutter, AVNRT, inducible ventricular tachycardia, and implantable cardioverter-defibrillator. Furthermore, this patient had a family history of sudden cardiac death and AF. The missense variant E825D was identified in a paroxysmal AF patient with early onset of disease at age 18. This patient also had AVNRT and several RAF procedures performed. The patient carrying the variant I999L had onset of paroxysmal AF at the age of 35 and also presented incomplete right bundle-branch block. This patient also carries the variant L10P in SCN3B, as previously reported. 32 The R1268Q variant were identified in 2 AF patients with onset of disease at age 23 (also had atrial flutter type II) and 31 (also had incomplete right bundle-branch block and several DC conversions). The patient with the rare variant C1523Y was diagnosed with paroxysmal AF at age 30, and in another paroxysmal AF patient with onset of disease at age 28, we identified the variant R1588Q. This latter patient had a radiofrequency ablation procedure for AVNRT. Interestingly, 4 of the rare variant carriers (≈40%) have AVNRT, in addition to AF, suggesting that the AV-node, and perhaps the autonomic nerve system, could play an important role in the genesis of AF in these patients. Positions of the variants found in lone AF cohort. The frequency and MAF of the alleles are reported from ESP6500 exome server. PolyPhen-2 prediction reports the possible effect of an amino acid substitution on protein structure and function based on Polymorphism Phenotyping-2 (PolyPhen-2) program. AA, African American; B, benign; D, disease causing; EA, European American; ESP 6500 exomes, exome variant server (chromosomes 1-22 and X); and MAF (%) (EA/AA/All), the minor-allele frequency in percent listed in the order of European American (EA), African American (AA), and all populations (All) (delimited by /). 
Electrophysiology
The electrophysiological properties of Na v 1.8 V1073, used as reference, and 4 variants were investigated by wholecell patch-clamping of Neuro-2A cells (Figures 2 and 3 ). We chose to analyze the V94G found in 2 unrelated patients and R1588Q variants based on the lowest variant frequency in the background population (not present in 2000 non-AF Danish exomes, data not shown), thereby reducing the risk of investigating a random finding. At the time of variant selection for functional studies, the 2 variants were not found in the exome sequencing database (n=5400), but later appeared in 1 exome for each variant when 1100 additional subjects were included in the database (n=6500). We also investigated the 2 nonsynonymous common variants A1073 and P1092. Figure 2A illustrates representative whole-cell currents from the Neuro-2A cells expressing V1073 and variant Na v 1.8 channels. Na v 1.8 channels are activated by depolarizing potentials more positive than −15 mV, with a fast activating current peaking at +15 mV ( Figure 2B) . A part of the current is rapidly inactivated, whereas a long lasting current component of ≈10% of the peak current level persists (Figure 2A) .
The V94G-Na v 1.8 channel does not conduct any current. The R1588Q variant showed peak current amplitude similar to reference channels; however, it had a faster time to peak, together with a >6 mV negative shift in the steady-state inactivation (V 1/2,V1073 −68.0±1.8 mV, V 1/2,R1588Q −74.4±2.5 mV; Figure 3B ). As −74.4 mV is close to the resting membrane potential of both atrial cardiomyocytes and neurons, this shift would be expected to play a major role in the channel availability, reducing the number of available channels as compared with V1073 Na v 1.8. The combined electrophysiological characterization of R1588Q would therefore be expected to result in a loss-of-function phenotype.
Compared with V1073 Na v 1.8 (−29.9±4.1 pA/pF), the 2 common variants expressed larger peak currents (A1073, −50.6±7.0 pA/pF; P1092, −61.4±8.5 pA/pF). Although the steady-state inactivation properties for A1073 and P1092 were not altered, the steady-state activation properties were shifted to more positive potentials for these 2 common variants (V 1/2,V1073 1.6±1.3 mV, V 1/2,A1073 7.1±1.3 mV, V 1/2,P1092 6.4±1.5 mV; Figure 3A ). For A1073, the time-dependent recovery from inactivation was decelerated ( Figure 3C ) and the timeto-peak accelerated ( Table 4 ). Both common variants have a slower current decay at several different potentials ( Figure 3E and 3F). Interestingly, the absolute sustained current level was increased for both A1073 and P1092 (V1073, 2.4±0.3 pA/pF; A1073, 3.9±0.5 pA/pF; P1092, 4.2±0.7pA/pF; Figure 3D ). For both reference Na v 1.8 channels and the 2 common variants, the sustained current level is 7% to 8% of the peak current at +15 mV. Hence, the increase in the absolute sustained current level of the variants is probably caused by the overall increased activity of these variant channels. Together, we found a depolarized shift in voltage-dependence of steadystate activation on A1073 and P1092 and decelerated recovery from inactivation on the A1073 variant. However, these 2 common variants also induced dramatically larger peak-current amplitude, a slower current decay phase from inactivation, and a pronounced larger persistent current. Hence, the combined electrophysiological changes of these 2 common variants would result in gain-of-function phenotypes.
Discussion
In the present study, we found 10 rare missense SCN10A variants in 225 lone AF patients in which the minor allele frequencies were <0.5% in the ESP. Furthermore, we showed that the A1073 variant (rs6795970) increases the risk of AF. Functional characterization of the 2 rarest variants of rs6795970 Figure 2 . Current recordings of SCN10A variants. A, Representative whole-cell current traces of Na v 1.8, using V1073 as reference construct, and mutant channels. Currents were recorded after a voltage step protocol with 5 mV increments from −70 mV to +50 mV, preceded with a −100 mV step. B, Current-voltage (I-V) relationship. The current is normalized to cell capacitance to provide a measure of Na + current density. C, Peak current density at 15 mV, 2-way analysis of variance with Bonferroni post-tests was applied to test for significant differences. Mean±SEM values are presented in Table 4 . B and C, n=13 to 15 for each group. Asterisks indicate the voltages at which the parameters were statistically different versus V1073. *P<0.05, **P<0.01, and ***P<0.001.
(with the lowest MAF) found in lone AF revealed reduced activity of Na v 1.8, whereas, conversely, the A1073 variant was found to increase activity of the channel.
The variant rs6800541, identified in previous GWAS studies, has been associated with PR-interval duration and is in close proximity to SCN10A. 10 This variant also decreases the odds ratio for AF (OR=0.92, P=1.4×10 −3 ). 10 Others have tested the association of rs6795970, which is in high linkage disequilibrium with rs6800541, with AF and showed the opposite trend; however, the association was not statistically significant. 10, 11 In the present study, we found that the G allele of rs6795970 increases the risk of AF in both lone AF (OR=1.33, P=4.6×10 −4 ) and general AF (OR=1.35, P=2.3×10 −5 ; Table 3 ). Functional studies of A1073 revealed several altered biophysical parameters, with the greatest one being increased peak and sustained current, as well as a slowing of fast inactivation. We therefore suggest that this variant has a gain-of-function phenotype, which seems to increase the risk of AF.
In lone AF patients, we identified 9 rare variants in SCN10A with MAF <0.5% in the ESP and one splice site donor variant in exon 4 ( Table 1 ). We performed electrophysiological patchclamp studies on the 2 rarest variants, V94G and R1588Q, Table 4 . Asterisks indicate the voltages at which the parameters were statistically different versus V1073 (*P<0.05).
which initially were found to be novel. Later, both variants were reported in ESP6500, but it should be noted that this is a nonselective database, where AF patients are not excluded. Because voltage-gated sodium channels are inactivated at voltage potentials close to the resting membrane potential, a negative shift in the steady-state inactivation, as seen for R1588Q, will result in a decreased availability of the channels. The V94G variant did not conduct any current. Hence, both tested variants found in lone AF patients have a loss-offunction phenotype. These data on the rare variants combined with the data on the A1073 common variant suggest that both gain and loss of functionality of the Na v 1.8 current may be involved in the development of AF. This has previously also been reported for the Na v 1.5 current. 29, [33] [34] [35] The I999L variant is a novel variant; however, because the patient also has a SCNB3 variant suspected to be disease causing, we did not include functional data of this variant. 32 Currently, the role of Na v 1.8 in cardiac electrophysiology remains unclear. If the primary role of Na v 1.8 channels is in the cardiomyocytes, both loss-and gain-of-function phenotypes could give rise to AF. This is analogous to what has been observed for Na v 1.5 channels, where both decreased Na V 1.5 current has been associated with AF via augmented propensity for conduction delay with a subsequent increased risk of re-entrant arrhythmias, and augmented current has been suggested to increase triggered activity. 29, 35, 36 Another possibility is that the Na v 1.8 peak current does not have a major effect because it is quantitatively much smaller than the Na v 1.5 peak current. But, because the sustained (late) Na v 1.8 current is 20to 50-fold higher than the corresponding Na v 1.5 late current, this depolarizing current could have a significant effect on the action potential duration and refractory period and thereby protect against AF. 37 Given the sparse expression of Na v 1.8 channels in cardiac myocytes, the association of SCN10A variants to AF could be mediated through neuronal input. One study has suggested that rs6795970 in SCN10A may modulate the ventricular heart rate response during AF through a modulation of the AV-node. 38 The AV-node is highly innervated by parasympathetic nerve fibers where Na v 1.8 is expressed. [39] [40] [41] Recognition of disease mechanisms overlap between the AF and AV-nodal re-entry tachycardia, and the fact that AVNRT may be the triggering factor for AF has been reported in several studies. [42] [43] [44] [45] Consistent with this notion, several of our paroxysmal AF patients with the rare variants have AVNRT ( Table 1) .
In AF patients, there has been substantial evidence of sympathetic tone-dependent AF. 46 Changes in autonomic tone, also known as sympathovagal imbalance, are important triggers in some forms of paroxysmal AF and also in the generation and maintenance of persistent AF. [41] [42] [43] With the expression of Na v 1.8 channels in vagal fibers and their absence in sympathetic fibers, it is possible that the observed effects on Na v 1.8 function of the different variants alters the sympathovagal balance. 19, 20, 22 We were able to examine 3 families for cosegregation of SCN10A variants identified in the respective probands (Table 1) , but none of the family members diagnosed with AF carried the variant of the proband. It is, however, not surprising that a monogenetic segregation pattern is absent because only a few reports have shown familial cosegregation of rare variants in AF. 47 In line with our study, it has been suggested that variation in the SCN5A is not the main cause of familial AF. 34 Whether a person with a rare variant develops AF probably depends on both the genetic background and environmental factors. Thus, the rare loss-of-function variants found in our study should most likely be regarded as important modifiers for the genesis of AF.
Perspective
In summary, this study reveals a correlation between variations in SCN10A and AF. The results thereby support the notion of SCN10A being important in cardiac physiology because genetic variations now have been found to be implicated in cardiac conduction, Brugada syndrome, and AF. The fact that SCN10A variations could play a promoting role in lone AF, as well as other types of AF, highlights the importance of further studies on the cellular and electrophysiological factors involved in the development of AF. Hence, our results further contribute to understanding the complexity of cardiac electrophysiology and suggest that SCN10A genotyping in the future could improve risk prediction. Data are presented as mean±SEM. Two-way analysis of variance combined with Bonferroni post-test was used to test for significant differences of peak current at 15 mV. The other parameters were tested by 2-tailed Student's t test. K indicates slope factor; N, the numbers of cells measured; T, time constant; and V 1/2 : midpoint potential. *P<0.05. †P<0.01 versus reference (V1073).
